文献速递消化系统肿瘤

自噬相关基因多态性预测接受FOLFIRI联合贝伐珠单抗治疗的转移性结直肠癌患者高血压发生:TRIBE与FIRE-3试验结果

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
PubMed 文献 · Eur J Cancer · 2017-03-26

研究纳入TRIBE试验(n=219,发现队列)和FIRE-3试验(n=234,验证队列)中接受一线FOLFIRI联合贝伐珠单抗治疗的转移性结直肠癌患者,以FIRE-3中接受FOLFIRI联合西妥昔单抗治疗的患者(n=204)为阴性对照,分析8个自噬相关基因的12个单核苷酸多态性(SNP)。结果显示FIP200 rs1129660变异与TRIBE队列中高血压显著相关,G等位基因携带者2-3级高血压发生率显著低于A/A基因型(3% vs 15%,OR 0.17;95%CI 0.02-0.73;P=0.009),FIRE-3验证队列中趋势一致但未达统计学显著(9% vs 20%,OR 0.43;95%CI 0.14-1.11;P=0.077),对照队列中未见此关联(12% vs 9%,OR 1.40;95%CI 0.45-4.04;P=0.60)。

要点

  • FIP200 rs1129660 G等位基因携带者2-3级高血压发生率在TRIBE队列为3%,低于A/A基因型的15%(OR 0.17;95%CI 0.02-0.73;P=0.009)。
  • FIRE-3验证队列中G等位基因携带者2-3级高血压发生率为9%,A/A基因型为20%(OR 0.43;95%CI 0.14-1.11;P=0.077),未达统计学显著。
  • 对照队列(FOLFIRI联合西妥昔单抗)中未见FIP200 rs1129660与高血压的关联(12% vs 9%,OR 1.40;95%CI 0.45-4.04;P=0.60)。

核心结论

  • 首次报道自噬相关FIP200基因多态性可能预测接受FOLFIRI联合贝伐珠单抗治疗的转移性结直肠癌患者高血压的发生。

研究设计与样本

  • 研究纳入TRIBE试验(n=219,发现队列)和FIRE-3试验(n=234,验证队列)中接受一线FOLFIRI联合贝伐珠单抗治疗的转移性结直肠癌患者,以FIRE-3中接受FOLFIRI联合西妥昔单抗治疗的患者(n=204)为阴性对照。
  • 采用PCR直接测序分析8个自噬相关基因(ATG3/5/8/13、beclin 1、FIP200、unc-51样激酶1、UVRAG)的12个单核苷酸多态性(SNP)。

主要发现

  • TRIBE队列中FIP200 rs1129660变异与高血压显著相关:G等位基因携带者2-3级高血压发生率为3%,A/A基因型为15%(OR 0.17;95%CI 0.02-0.73;P=0.009)。
  • FIRE-3验证队列中G等位基因携带者2-3级高血压发生率为9%,A/A基因型为20%(OR 0.43;95%CI 0.14-1.11;P=0.077),未达统计学显著。
  • 对照队列中G等位基因携带者2-3级高血压发生率为12%,A/A基因型为9%(OR 1.40;95%CI 0.45-4.04;P=0.60),未见关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding and thromboembolism. To date, there is no biomarker that predicts anti-VEGF-associated toxicity. As autophagy inhibits angiogenesis, we hypothesised that single-nucleotide polymorphisms (SNPs) within autophagy-related genes may predict bevacizumab-mediated toxicity in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with mCRC treated with first-line FOLFIRI and bevacizumab in two phase III randomised trials, namely the TRIBE trial (n = 219, discovery cohort) and the FIRE-3 trial (n = 234, validation cohort) were included in this study. Patients receiving treatment with FOLFIRI and cetuximab (FIRE-3, n = 204) served as a negative control. 12 SNPs in eight autophagy-related genes (ATG3/5/8/13, beclin 1, FIP200, unc-51-like kinase 1, UVRAG) were analysed by PCR-based direct sequencing. RESULTS: The FIP200 rs1129660 variant showed significant associations with hypertension in the TRIBE cohort. Patients harbouring any G allele of the FIP200 rs1129660 SNP showed a significantly lower rate of grade 2-3 hypertension compared with the A/A genotype (3% versus 15%, odds ratio [OR] 0.17; 95% confidence interval [CI], 0.02-0.73; P = 0.009). Similarly, G allele carriers of the FIP200 rs1129660 SNP were less likely to develop grade 2-3 hypertension than patients with an A/A genotype in the FIRE-3 validation cohort (9% versus 20%, OR 0.43; 95% CI, 0.14-1.11; P = 0.077), whereas this association could not be observed in the control cohort (12% versus 9%, OR 1.40; 95% CI, 0.45-4.04; P = 0.60). CONCLUSION: This is the first report demonstrating that polymorphisms in the autophagy-related FIP200 gene may predict hypertension in patients with mCRC treated with FOLFIRI and bevacizumab.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Berger MD, Yamauchi S, Cao S, et al. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017. PMID: 28347919. doi:10.1016/j.ejca.2017.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。